Pre-made Duvortuxizumab benchmark antibody ( Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Duvortuxizumab benchmark antibody (Bispecific scFv with Crossover, anti-CD19;CD3E therapeutic antibody, Anti-B4/CVID3;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]
| Products Name (INN Index) | Pre-Made Duvortuxizumab biosimilar, Bispecific scFv with Crossover, Anti-CD19;CD3E antibody: Anti-B4/CVID3;T3E/TCRE/IMD18 therapeutic antibody |
|---|---|
| INN Name | Duvortuxizumab |
| Target | CD19,CD3E |
| Format | Bispecific scFv with Crossover |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | NA |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | Janssen Biotech,MacroGenics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Diffuse large B cell lymphoma,Follicular lymphoma,Non-Hodgkin's lymphoma,Precursor B-cell lymphoblastic leukaemia-lymphoma |
| Development Tech | Dual-Affinity?Re-targenting (DART?) |
| Previous Name | NA |
| Gm Offical Target Name | CD19,CD3E |
| Package |
